Back to top
more

Annexon (ANNX)

(Delayed Data from NSDQ)

$4.70 USD

4.70
1,430,749

+0.11 (2.40%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $4.69 -0.01 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ANNX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Annexon, Inc. [ANNX]

Reports for Purchase

Showing records 1 - 19 ( 19 total )

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/27/2024

Company Report

Pages: 7

ANX005’s GBS Trial Design Superior to that of Eculizumab-Our Thoughts

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

03/07/2024

Industry Report

Pages: 3

Live from AD/PD 2024 Lisbon-Mechanistic Insights on ARIA Exploring the Role of Classical Complement Pathway Activation

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

03/04/2024

Company Report

Pages: 4

Differentiated GBS Trial Design Encouraging for ANX005; Reiterate Buy and $30 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

12/21/2023

Daily Note

Pages: 4

ANX1502 and ANX007 Promises Differentiated Solution to Current SOCs, Rejuvenates Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

11/14/2023

Company Report

Pages: 7

mEGOS, A Predictive Modeling Approach Aims to Improve GBS Phase 3 Trial Outcome

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

08/08/2023

Company Report

Pages: 7

Annexon Tests C1q’s Unique Role in Complement Driven Diseases; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

07/31/2023

Daily Note

Pages: 4

ANX007 Offers a Differentiated Approach in Preserving Vision-Reporting from the Emerald City

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

05/25/2023

Daily Note

Pages: 4

Focusing on Protection from Vision Loss in GA is Unique-Thoughts on ARCHER

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

05/09/2023

Company Report

Pages: 7

Attacking C1q in GA Differentiates ARCHER; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

03/07/2023

Company Report

Pages: 7

Thoughts on Annexon’s GA Program; Reit Buy and $30 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

11/04/2022

Company Report

Pages: 7

Trial Design for ARCHER is Key to Evaluating C1q Hypothesis; Reit. Buy and $30 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

08/09/2022

Company Report

Pages: 7

Focus on the Upcoming Phase 2 WAIHA Data Readout in 2H2022; Reit. Buy and $30 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

06/07/2022

Daily Note

Pages: 4

Phase 2 HD Data Validates ANX005''s MOA and Opens Potential Pathway For a Confirmatory Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

05/10/2022

Company Report

Pages: 7

What to Expect in the Upcoming WAIHA Data Readout in 2H2022; Reit Buy and Lower PT to $30

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

03/02/2022

Company Report

Pages: 7

Phase 2 HD Data in 2Q22 Might Establish the Role of Complement in Neurodegeneration

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

01/05/2022

Daily Note

Pages: 5

Interim HD data Indicate ANX005’s Robust Target Engagement in the CNS

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

12/14/2021

Daily Note

Pages: 4

ANX009 Clinical Readout at ASH Showcases Diversified Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

11/30/2021

Company Report

Pages: 93

Annexon’s Differentiated Platform Targets Complement Biology; Initiating With a Buy Rating and $40 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 75.00

Research Provided by a Third Party

Company: Annexon, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ANNX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party